INVESTMENT & DUE DILIGENCE
PortfolioScreen
A structured scientific and commercial view of assets, pipelines and investment opportunities. Make the trade-offs visible before committing resources or capital.
For biotech teams prioritizing a pipeline and investors deciding where to focus diligence.
A prioritized asset decision pack or an investment committee diligence memo, shaped around your decision.
01 / Comparable asset scorecards
Agreed criteria, transparent weights and evidence behind each assessment.
02 / A focused risk register
Scientific, clinical and commercial uncertainties, with the questions that could change the decision.
03 / A decision-ready shortlist
Priorities, scenario sensitivities and a clear next-diligence agenda.
ILLUSTRATIVE EXAMPLE · 2-PAGE PDF
An illustrative comparison of three fictional development assets, including a weighted scorecard and evidence-gated diligence plan.
Fictional scenario and sample outputs, created to show the format and depth of an engagement. This is not completed client work.
01 / Frame the decision
Agree the mandate, assets, time horizon, available evidence and decision criteria.
02 / Challenge the evidence
Review scientific rationale, development risk, competitive position and commercial assumptions.
03 / Prioritize the next move
Compare options, test the ranking and define what must be validated before a commitment.
Scope, timing and deliverables are agreed for each engagement.